Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human

Molecular and Cellular Proteomics

Volumn 12, Issue 12, 2013, Pages 3793-3802

  Wang, Ding ^a   Fang, Caiyun ^a,b   Zong, Nobel C ^a,b   Liem, David A ^a   Cadeiras, Martin ^a   Scruggs, Sarah B ^a   Yu, Hongxiu ^b   Kim, Allen K ^a   Yang, Pengyuan ^b   Deng, Mario ^a   Lu, Haojie ^b   Ping, Peipei ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; NICOTINAMIDE; PROTEASOME; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLISIONALLY ACTIVATED DISSOCIATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REPERFUSION INJURY; SHAM PROCEDURE; TANDEM MASS SPECTROMETRY; ULTRACENTRIFUGATION;

ACETYLATION; ANIMALS; CHROMATOGRAPHY, LIQUID; GENE EXPRESSION REGULATION; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LYSINE; MALE; MICE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; VALPROIC ACID;

EID: 84890645801     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M113.028332     Document Type: Article

References (57)

1. Glembotski, C. C. (2012) Clarifying the cardiac proteasome paradox: protein quality control. Circ. Res. 111, 509-512
2. Wang, X., Yen, J., Kaiser, P., and Huang, L. (2010) Regulation of the 26S proteasome complex during oxidative stress. Sci. Signal. 3, ra88
3. Scruggs, S. B., Ping, P., and Zong, C. (2011) Heterogeneous cardiac proteasomes: mandated by diverse substrates? Physiology 26, 106-114
4. Gomes, A. V., Waddell, D. S., Siu, R., Stein, M., Dewey, S., Furlow, J. D., and Bodine, S. C. (2012) Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. FASEB J. 26, 2986-2999
5. Powell, S. R., Herrmann, J., Lerman, A., Patterson, C., and Wang, X. (2012) The ubiquitin-proteasome system and cardiovascular disease. Prog. Mol. Biol. Transl. Sci. 109, 295-346
6. Chondrogianni, N., Tzavelas, C., Pemberton, A. J., Nezis, I. P., Rivett, A. J., and Gonos, E. S. (2005) Overexpression of proteasome beta5 assembled subunit increases the mount of proteasome and confers ameliorated response to oxidative stress and higher survival rates. J. Biol. Chem. 280, 11840-11850
7. Ding, Q., Martin, S., Dimayuga, E., Bruce-Keller, A. J., and Keller, J. N. (2006) LMP2 knock-out mice have reduced proteasome activities and increased levels of oxidatively damaged proteins. Antioxid. Redox. Signal 8, 130-135
8. Li, J., Powell, S. R., and Wang, X. (2011) Enhancement of proteasome function by A28α overexpression protects against oxidative stress. FASEB J. 25, 883-893
9. Voortman, J., and Giaccone, G. (2006) Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer 6, 129
10. Dasanu, C. A. (2011) Complete heart block secondary to bortezomib use in multiple myeloma. J. Oncol. Pharm. Pract. 17, 282-284
11. Cole, H. A., Frearson, N., Moir, A. J., Perry, S. V., and Solaro, R. J. (1976) Phosphorylation of cardiac myofibrillar proteins. Recent Adv. Stud. Cardiac. Struct. Metab. 11, 111-120
12. Lu, Z., Scott, I., Webster, B. R., and Sack, M. N. (2009) The emerging characterization of lysine residue deacetylation on the modulation of mitochondrial function and cardiovascular biology. Circ. Res. 105, 830-841
13. Zhang, J., Sprung, R., Pei, J., Tan, X., Kim, S., Zhu, H., Liu, C. F., Grishin, N. V., and Zhao, Y. (2009) Lysine acetylation is a highly abundant and evolutionarily conserved modification in Escherichia coli. Mol. Cell. Proteomics 8, 215-225
14. Zong, C., Gomes, A. V., Drews, O., Li, X., Young, G. W., Berhane, B., Qiao, X., French, S. W., Bardag-Gorce, F., and Ping, P. (2006) Regulation of murine cardiac 20S proteasomes: role of associating partners. Circ. Res. 99, 372-380
15. Bulteau, A. L., Lundberg, K. C., Humphries, K. M., Sadek, H. A., Szweda, P. A., Friguet, B., and Szweda, L. I. (2001) Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 276, 30057-30063
16. Drews, O., Tsukamoto, O., Liem, D., Streicher, J., Wang, Y., and Ping, P. (2010) Differential regulation of proteasome function in isoproterenolinduced cardiac hypertrophy. Circ. Res. 107, 1094-1101
17. Zhao, S., Xu, W., Jiang, W., Yu, W., Lin, Y., Zhang, T., Yao, J., Zhou, L., Zeng, Y., Li, H., Li, Y., Shi, J., An, W., Hancock, S. M., He, F., Qin, L., Chin, J., Yang, P., Chen, X., Lei, Q., Xiong, Y., and Guan, K. L. (2010) Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000-1004
18. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., and Mann, M. (2009) Lysine acetylation targets protein complexes and co- regulates major cellular functions. Science 325, 834-840
19. Backs, J., and Olson, E. N. (2006) Control of cardiac growth by histone acetylation/deacetylation. Circ. Res. 98, 15-24
20. Lv, L., Li, D., Zhao, D., Lin, R., Chu, Y., Zhang, H., Zha, Z., Liu, Y., Li, Z., Xu, Y., Wang, G., Huang, Y., Xiong, Y., Guan, K. L., and Lei, Q. Y. (2011) Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 42, 719-730
21. Jiang, W., Wang, S., Xiao, M., Lin, Y., Zhou, L., Lei, Q., Xiong, Y., Guan, K. L., and Zhao, S. (2011) Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol. Cell 43, 33-44
22. Wang, G., Liem, D. A., Vondriska, T. M., Honda, H. M., Korge, P., Pantaleon, D. M., Qiao, X., Wang, Y., Weiss, J. N., and Ping, P. (2005) Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. Am. J. Physiol. Heart Circ. Physiol. 288, H1290-H1295
23. Guo, Y., Jones, W. K., Xuan, Y. T., Tang, X. L., Bao, W., Wu, W. J., Han, H., Laubach, V. E., Ping, P., Yang, Z., Qiu, Y., and Bolli, R. (1999) The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc. Natl. Acad. Sci. U.S.A. 96, 11507-11512
24. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
25. Lu, H., Zong, C., Wang, Y., Young, G. W., Deng, N., Souda, P., Li, X., Whitelegge, J., Drews, O., Yang, P. Y., and Ping, P. (2008) Revealing the dynamics of the 20 S proteasome phosphoproteome: a combined CID and electron transfer dissociation approach. Mol. Cell. Proteomics 7, 2073-2089
26. Deng, N., Zhang, J., Zong, C., Wang, Y., Lu, H., Yang, P., Wang, W., Young, G. W., Wang, Y., Korge, P., Lotz, C., Doran, P., Liem, D. A., Apweiler, R., Weiss, J. N., Duan, H., and Ping, P. (2011) Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. Mol. Cell. Proteomics 10, M110.000117
27. Zong, N., Li, H., Li, H., Lam, M. P., Jimenez, R. C., Kim, C. S., Deng, N., Kim, A. K., Choi, J. H., Zelaya, I., Liem, D. A., Meyer, D., Odeberg, J., Fang, C., Lu, H. J., Xu, T., Weiss, J. N., Duan, H., Uhlen, M., Yates, J., 3rd, Apweiler, R., Ge, J., Hermjakob, H., and Ping, P. (2013) Integration of cardiac proteome biology and medicine by a specialized knowledgebase. Circ. Res. [Epub ahead of Print]
28. Predmore, J. M., Wang, P., Davis, F., Bartolone, S., Westfall, M. V., Dyke, D. B., Pagani, F., Powell, S. R., and Day, S. M. (2010) Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. Circulation 121, 997-1004
29. Starheim, K. K., Gevaert, K., and Arnesen, T. (2012) Protein N-terminal acetyltransferases: when the start matters. Trends Biochem. Sci. 37, 152-161
30. Gomes, A. V., Zong, C., Edmondson, R. D., Li, X., Stefani, E., Zhang, J., Jones, R. C., Thyparambil, S., Wang, G. W., Qiao, X., Bardag-Gorce, F., and Ping, P. (2006) Mapping the murine cardiac 26S proteasome complexes. Circ. Res. 99, 362-371
31. Wang, X., Chen, C. F., Baker, P. R., Chen, P. L., Kaiser, P., and Huang, L. (2007) Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. Biochemistry 46, 3553-3565
32. Chen, P., and Hochstrasser, M. (1996) Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 86, 961-972
33. Seemuller, E., Lupas, A., and Baumeister, W. (1996) Autocatalytic processing of the 20S proteasome. Nature 382, 468-471
34. Kim, S. C., Sprung, R., Chen, Y., Xu, Y., Ball, H., Pei, J., Cheng, T., Kho, Y., Xiao, H., Xiao, L., Grishin, N. V., White, M., Yang, X. J., and Zhao, Y. (2006) Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol. Cell 23, 607-618
35. Liu, J., Wang, Y., Li, L., Zhou, L., Wei, H., Zhou, Q., Liu, J., Wang, W., Ji, L., Shan, P., Wang, Y., Yang, Y., Jung, S. Y., Zhang, P., Wang, C., Long, W., Zhang, B., and Li, X. (2013) Site-specific acetylation of the proteasome activator REGgamma directs its heptameric structure and functions. J. Biol. Chem. 288, 16567-16578
36. Wang, B., Liu, K., Lin, H. Y., Bellam, N., Ling, S., and Lin, W. C. (2010) 14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol. Cell. Biol. 30, 1508-1527
37. Bardag-Gorce, F., and French, S. W. (2011) Delta-aminolevulinic dehydratase is a proteasome interacting protein. Exp. Mol. Pathol. 91, 485-489
38. Conconi, M., Petropoulos, I., Emod, I., Turlin, E., Biville, F., and Friguet, B. (1998) Protection from oxidative inactivation of the 20S proteasome by heat-shock protein 90. Biochem. J. 333 (Pt 2), 407-415
39. Kageyama, S., Tsomides, T. J., Fukusen, N., Papayannopoulos, I. A., Eisen, H. N., and Sykulev, Y. (2001) Potent cytolytic response by a CD8+ CTL clone to multiple peptides from the same protein in association with an allogeneic class 1 MHC molecule. J. Immunol. 166, 3028-3034
40. Han, Z., Zhong, L., Srivastava, A., and Stacpoole, P. W. (2008) Pyruvate dehydrogenase complex deficiency caused by ubiquitination and proteasome- mediated degradation of the E1 subunit. J. Biol. Chem. 283, 237-243
41. Drews, O., Wildgruber, R., Zong, C., Sukop, U., Nissum, M., Weber, G., Gomes, A. V., and Ping, P. (2007) Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol. Cell. Proteomics 6, 2021-2031
42. Lam, M. P., Lau, E., Scruggs, S. B., Wang, D., Kim, T. Y., Liem, D. A., Zhang, J., Ryan, C. M., Faull, K. F., and Ping, P. (2013) Site-specific quantitative analysis of cardiac mitochondrial protein phosphorylation. J. Proteomics 81, 15-23
43. Unno, M., Mizushima, T., Morimoto, Y., Tomisugi, Y., Tanaka, K., Yasuoka, N., and Tsukihara, T. (2002) The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure 10, 609-618
44. Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., and Grant, S. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115, 4478-4487
45. Churchill, E. N., Ferreira, J. C., Brum, P. C., Szweda, L. I., and Mochly-Rosen, D. (2010) Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion. Cardiovasc. Res. 85, 385-394
46. Divald, A., Kivity, S., Wang, P., Hochhauser, E., Roberts, B., Teichberg, S., Gomes, A. V., and Powell, S. R. (2010) Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ. Res. 106, 1829-1838
47. Li, J., Horak, K. M., Su, H., Sanbe, A., Robbins, J., and Wang, X. (2011) Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J. Clin. Invest. 121, 3689-3700
48. Guan, J. S., Haggarty, S. J., Giacometti, E., Dannenberg, J. H., Joseph, N., Gao, J., Nieland, T. J., Zhou, Y., Wang, X., Mazitschek, R., Bradner, J. E., DePinho, R. A., Jaenisch, R., and Tsai, L. H. (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55-60
49. Marks, P. A., and Dokmanovic, M. (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497-1511
50. Adcock, I. M. (2007) HDAC inhibitors as anti-inflammatory agents. Br. J. Pharmacol. 150, 829-831
51. Munster, P., Marchion, D., Bicaku, E., Lacevic, M., Kim, J., Centeno, B., Daud, A., Neuger, A., Minton, S., and Sullivan, D. (2009) Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase 1/2 trial of valproic acid and epirubicin/ FEC. Clin. Cancer Res. 15, 2488-2496
52. Friday, B. B., Anderson, S. K., Buckner, J., Yu, C., Giannini, C., Geoffroy, F., Schwerkoske, J., Mazurczak, M., Gross, H., Pajon, E., Jaeckle, K., and Galanis, E. (2012) Phase 2 trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 14, 215-221
53. Burba, I., Colombo, G. I., Staszewsky, L. I., De Simone, M., Devanna, P., Nanni, S., Avitabile, D., Molla, F., Cosentino, S., Russo, I., De Angelis, N., Soldo, A., Biondi, A., Gambini, E., Gaetano, C., Farsetti, A., Pompilio, G., Latini, R., Capogrossi, M. C., and Pesce, M. (2011) Histone deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34 cells. PloS One 6, e22158
54. Zhang, Z., Tong, N., Gong, Y., Qiu, Q., Yin, L., Lv, X., and Wu, X. (2011) Valproate protects the retina from endoplasmic reticulum stress-induced apoptosis after ischemia- reperfusion injury. Neurosci. Lett. 504, 88-92
55. Papi, A., Ferreri, A. M., Guerra, F., and Orlandi, M. (2012) Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines. Anticancer Res. 32, 2855-2862
56. Ganslmayer, M., Konturek, P., Herold, C., Neurath, M. F., and Zopf, S. (2012) Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo. Anticancer Res. 32, 5263-5269
57. Eikel, D., Lampen, A., and Nau, H. (2006) Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem. Res. Toxicol. 19, 272-278